Literature DB >> 9274482

Liver iron concentration and distribution in chronic hepatitis C before and after interferon treatment.

E Boucher1, A Bourienne, P Adams, B Turlin, P Brissot, Y Deugnier.   

Abstract

BACKGROUND: Recent studies have suggested that, in patients with chronic hepatitis C, elevated iron stores are predictive of a poor response to interferon. AIMS: To assess liver iron concentration and distribution before and after interferon treatment in patients with hepatitis C in order to evaluate further the role of iron in the pathogenesis of hepatitis C. PATIENTS: Fifty-five patients with hepatitis C treated with alpha interferon for six months.
METHODS: Patients were evaluated for liver iron concentration (normal value < 36 mumol/g), and liver iron distribution before and six months after therapy.
RESULTS: At entry: liver iron concentration was elevated in 16/55 patients (29%); iron staining (Perls' staining) was found in 31/55 patients (56%) mainly within Kupffer and endothelial cells. Iron load was significantly higher in patients with the most histological inflammatory activity. Following treatment: liver iron concentration decreased significantly (40 (24) to 30 (17) mumol/g, p = 0.001); this was related to iron depletion in mesenchymal cells. Iron depletion occurred regardless of the response to therapy. Elevated liver iron concentration was not found to be a predictive factor of failure of interferon.
CONCLUSION: Although liver iron stores were usually normal or only slightly elevated in patients with chronic hepatitis C, biochemical and histological liver iron content decreased following treatment due to the diminution in mesenchymal iron deposits. Iron depletion was interpreted as both a consequence of the anti-inflammatory effect of treatment and a factor of improvement in liver histology.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9274482      PMCID: PMC1027238          DOI: 10.1136/gut.41.1.115

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  18 in total

Review 1.  Side effects of alpha interferon.

Authors:  P F Renault; J H Hoofnagle
Journal:  Semin Liver Dis       Date:  1989-11       Impact factor: 6.115

2.  Iron stores, response to alpha-interferon therapy, and effects of iron depletion in chronic hepatitis C.

Authors:  A Piperno; M Sampietro; R D'Alba; L Roffi; S Fargion; S Parma; C Nicoli; N Corbetta; M Pozzi; V Arosio; G Boari; G Fiorelli
Journal:  Liver       Date:  1996-08

Review 3.  Hepatic blood flow: morphologic aspects and physiologic regulation.

Authors:  A M Rappaport
Journal:  Int Rev Physiol       Date:  1980

4.  Measurement of liver-iron concentration in needle-biopsy specimens.

Authors:  M Barry; S Sherlock
Journal:  Lancet       Date:  1971-01-16       Impact factor: 79.321

5.  Effect of ursodeoxycholic acid on liver iron stores and distribution in rats with normal or iron-supplemented diet.

Authors:  O Loréal; N Chenoufi; B Turlin; C Haziza-Pigeon; J Y Robert; G Lescoat; H Mathiex-Fortunet; Y Deugnier; P Brissot
Journal:  Liver       Date:  1997-02

6.  Serum ferritin in patients with iron overload and with acute and chronic liver diseases.

Authors:  J Prieto; M Barry; S Sherlock
Journal:  Gastroenterology       Date:  1975-03       Impact factor: 22.682

7.  Assessment of liver iron content in 271 patients: a reevaluation of direct and indirect methods.

Authors:  P Brissot; M Bourel; D Herry; J P Verger; M Messner; C Beaumont; F Regnouard; B Ferrand; M Simon
Journal:  Gastroenterology       Date:  1981-03       Impact factor: 22.682

8.  Gamma-interferon modulates human monocyte/macrophage transferrin receptor expression.

Authors:  R Taetle; J M Honeysett
Journal:  Blood       Date:  1988-06       Impact factor: 22.113

9.  Response to interferon alpha therapy is influenced by the iron content of the liver.

Authors:  D H Van Thiel; L Friedlander; S Fagiuoli; H I Wright; W Irish; J S Gavaler
Journal:  J Hepatol       Date:  1994-03       Impact factor: 25.083

10.  Differentiation between heterozygotes and homozygotes in genetic hemochromatosis by means of a histological hepatic iron index: a study of 192 cases.

Authors:  Y M Deugnier; B Turlin; L W Powell; K M Summers; R Moirand; L Fletcher; O Loréal; P Brissot; J W Halliday
Journal:  Hepatology       Date:  1993-01       Impact factor: 17.425

View more
  17 in total

1.  Low hepatic iron concentration: evaluation of two complementary methods, colorimetric assay and iron histological scoring.

Authors:  F Imbert-Bismut; F Charlotte; B Turlin; L Khalil; A Piton; P Brissot; Y Le Charpentier; J Delattre; P Opolon; Y Deugnier; T Poynard
Journal:  J Clin Pathol       Date:  1999-06       Impact factor: 3.411

2.  Novel assessment of hepatic iron distribution by synchrotron radiation X-ray fluorescence microscopy.

Authors:  Hisoka Kinoshita; Yuichi Hori; Takumi Fukumoto; Takuji Ohigashi; Kunio Shinohara; Yoshitake Hayashi; Yonson Ku
Journal:  Med Mol Morphol       Date:  2010-03-26       Impact factor: 2.309

3.  Iron levels in hepatocytes and portal tract cells predict progression and outcomes of patients with advanced chronic hepatitis C.

Authors:  Richard W Lambrecht; Richard K Sterling; Deepa Naishadham; Anne M Stoddard; Thomas Rogers; Chihiro Morishima; Timothy R Morgan; Herbert L Bonkovsky
Journal:  Gastroenterology       Date:  2011-02-15       Impact factor: 22.682

4.  Iron increases HMOX1 and decreases hepatitis C viral expression in HCV-expressing cells.

Authors:  Wei-Hong Hou; Lisa Rossi; Ying Shan; Jian-Yu Zheng; Richard-W Lambrecht; Herbert-L Bonkovsky
Journal:  World J Gastroenterol       Date:  2009-09-28       Impact factor: 5.742

5.  Hemochromatosis and transferrin receptor gene polymorphisms in chronic hepatitis C: impact on iron status, liver injury and HCV genotype.

Authors:  Sven G Gehrke; Wolfgang Stremmel; Inge Mathes; Hans-Dieter Riedel; Karin Bents; Birgit Kallinowski
Journal:  J Mol Med (Berl)       Date:  2003-10-14       Impact factor: 4.599

Review 6.  HFE gene in primary and secondary hepatic iron overload.

Authors:  Giada Sebastiani; Ann-P Walker
Journal:  World J Gastroenterol       Date:  2007-09-21       Impact factor: 5.742

7.  Assessment of hepatic fibrosis in pediatric cases with hepatitis C virus in Egypt.

Authors:  Manal A El-Hawary; Mona S El-Raziky; Gamal Esmat; Hanan Soliman; Amr Abouzied; Maissa El-Raziky; Wafaa El-Akel; Rokaya El-Sayed; Fatma Shebl; Abdel-Aziz Shaheen; Hanaa El-Karaksy
Journal:  World J Gastroenterol       Date:  2007-05-28       Impact factor: 5.742

8.  Hepcidin expression in the liver: relatively low level in patients with chronic hepatitis C.

Authors:  Naoki Fujita; Ryosuke Sugimoto; Masaki Takeo; Naohito Urawa; Rumi Mifuji; Hideaki Tanaka; Yoshinao Kobayashi; Motoh Iwasa; Shozo Watanabe; Yukihiko Adachi; Masahiko Kaito
Journal:  Mol Med       Date:  2007 Jan-Feb       Impact factor: 6.354

9.  Mouse aminoacylase 3: a metalloenzyme activated by cobalt and nickel.

Authors:  Kirill Tsirulnikov; Natalia Abuladze; Debra Newman; Sergey Ryazantsev; Talya Wolak; Nathaniel Magilnick; Myong-Chul Koag; Ira Kurtz; Alexander Pushkin
Journal:  Biochim Biophys Acta       Date:  2009-04-09

Review 10.  Liver pathology of hepatitis C, beyond grading and staging of the disease.

Authors:  Sadhna Dhingra; Stephen C Ward; Swan N Thung
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.